Serum biomarkers for the differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma.
World J Gastrointest Oncol
; 15(2): 268-275, 2023 Feb 15.
Article
en En
| MEDLINE
| ID: mdl-36908319
ABSTRACT
Autoimmune pancreatitis (AIP), a chronic inflammation caused by the immune system attacking the pancreas, usually presents imaging and clinical features that overlap with those of pancreatic ductal adenocarcinoma (PDAC). Serum biomarkers, substances that quantitatively change in sera during disease development, are a promising non-invasive tool with high utility for differentiating between these diseases. In this way, the presence of AIP is currently suspected when serum concentrations of immunoglobulin G4 (IgG4) antibody are elevated. However, this approach has some drawbacks. Notably, IgG4 antibody concentrations are also elevated in sera from some patients with PDAC. This review focuses on the most recent and relevant serum biomarkers proposed to differentiate between AIP and PDAC, evaluating the usefulness of immunoglobulins, autoantibodies, chemokines, and cytokines. The proposed serum biomarkers have proven useful, although most studies had a small sample size, did not examine their presence in patients with PDAC, or did not test them in humans. In addition, current evidence suggests that a single serum biomarker is unlikely to accurately differentiate these diseases and that a set of biomarkers will be needed to achieve adequate specificity and sensitivity, either alone or in combination with clinical data and/or radiological images.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
World J Gastrointest Oncol
Año:
2023
Tipo del documento:
Article
País de afiliación:
España